dc.contributor.author | Umar, Rashida Muhammad | |
dc.contributor.author | Can, Zeynep Yeşim | |
dc.contributor.author | Güven Eke, Ece | |
dc.contributor.author | Karataş Koçberber, Emine | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.date.accessioned | 2023-05-08T07:30:08Z | |
dc.date.available | 2023-05-08T07:30:08Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Umar, R. M., Can, Z. Y., Güven Eke, E., Karataş Koçberber, E. ve Ölmez, Ö. F. (2023). The prevalence of drug-drug interactions and reported therapy related side-effects in oncology out-patients. Clinical and Experimental Health Sciences, 13(1), 212-217. https://doi.org/10.33808/clinexphealthsci.1099582 | en_US |
dc.identifier.issn | 2459-1459 | |
dc.identifier.uri | https://doi.org/10.33808/clinexphealthsci.1099582 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10914 | |
dc.description.abstract | Objective: The use of multiple medications in cancer patients is unavoidable; thus, adverse drug-drug interactions are frequent. This study aims to assess the prevalence of potential drug interactions in oncology patients visiting the outpatient chemotherapy unit. Method: Demographic and health-related information of patients visiting an outpatient chemotherapy unit was recorded using a pre-prepared form. A comprehensive list of all concurrently used medications was compiled and checked for interactions with the Micromedex online drug interaction tool.Results: A total of 179 adult patients were included. We recorded an average of 9.3 drugs per patient with 79 patients using more than 10 drugs. A total of 1671 drugs including 303 chemotherapeutic agents were assessed for drug-drug interactions. A total of 374 interactions, of which 203 were significant, were recorded in 118 (65.9%) patients with an average of 3.2 interactions per patient. Only 46 major interactions were recorded for anticancer agents. Cyclophosphamide (n=13) and cisplatin (n=12) were involved in most interactions. The number of interactions correlated with the number of drugs used (p=.001) and the presence of comorbidities (p=.002). The presence of comorbidities increased the risk of interaction by 1.21 (p=.04). Recorded side effects were not correlated to drug interactions. Conclusion: Medication review in cancer patients is essential in establishing all medications used by patients. Routine assessment in terms of potential drug interactions and evaluation of these interactions by a qualified pharmacist may help in optimizing patient outcomes. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Marmara University | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Cancer Patients | en_US |
dc.subject | Antineoplastic Agents | en_US |
dc.subject | Drug-Drug Interaction | en_US |
dc.subject | Side Effects | en_US |
dc.subject | Polypharmacy | en_US |
dc.title | The prevalence of drug-drug interactions and reported therapy related side-effects in oncology out-patients | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Clinical and Experimental Health Sciences | en_US |
dc.department | İstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Klinik Eczacılık Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-8902-7274 | en_US |
dc.authorid | 0000-0002-9053-5038 | en_US |
dc.authorid | 0000-0001-7934-7039 | en_US |
dc.identifier.volume | 13 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 212 | en_US |
dc.identifier.endpage | 217 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.33808/clinexphealthsci.1099582 | en_US |
dc.institutionauthor | Umar, Rashida Muhammad | |
dc.institutionauthor | Güven Eke, Ece | |
dc.institutionauthor | Ölmez, Ömer Fatih | |
dc.identifier.wos | 000960484800028 | en_US |
dc.identifier.trdizinid | 1162648 | en_US |